Drugs - Xagena.net - Update in Medicine

Search results for "Testosterone"

FDA is investigating risk of cardiovascular events with Testosterone products

The FDA ( Food and Drug Administration ) is investigating the risk of stroke, myocardial infarction, and death in men taking FDA-approved Testosterone products. FDA has been monitoring this risk and ... read article

Xofigo for advanced prostate cancer, FDA approved

The FDA ( Food and Drug Administration ) has approved Xofigo ( Radium Ra 223 dichloride ) to treat men with symptomatic late-stage castration-resistant prostate cancer that has spread to bones but not ... read article

Hepatotoxicity remains an important safety concern for all antiandrogen drugs

Antiandrogens are a class of drugs used in androgen deprivation therapy for the treatment of advanced or metastatic prostate cancer. They are classified into two groups: nonsteroidal antiandrogens ( F ... read article

Zytiga for late-stage prostate cancer, FDA approves

The FDA ( Food and Drug Administration ) has approved Zytiga ( Abiraterone acetate ) in combination with Prednisone ( a steroid ) to treat patients with late-stage ( metastatic ) castration-resistant ... read article

Abiraterone improves survival in metastatic castration-resistant prostate cancer

Patients with metastatic castration-resistant prostate cancer who have progressed after chemotherapy live significantly longer if treated with the drug Abiraterone ( Zytiga )compared to placebo. Pat ... read article

REDUCE trial: Dutasteride in the prevention of prostate tumor

An editorial about REDUCE ( Reduction by Dutasteride of Prostate Cancer Events ) trial by Fritz H Schröder and Monique J Roobol has been published in the European Urology. The final report of the R ... read article

Dutasteride reduces risk of prostate carcinoma diagnosis in high-risk men

Dutasteride ( Avodart ) has shown to reduce the risk of a prostate cancer diagnosis by 23 percent in men with an increased risk of the disease. The results are reported in the New England Journal of ... read article

Increase in risk of diabetes and cardiovascular diseases in men treated with GnRH agonists

GnRH ( Gonadotropin-Releasing Hormone ) agonists, a class of drugs primarily used to treat men with prostate cancer, have been associated with a small increased risk for diabetes, myocardial infarctio ... read article

Potential risk of male breast cancer with Finasteride

Finasteride is an inhibitor of type II 5-alpha-reductase, an enzyme that metabolises testosterone into the more potent androgen, dihydrotestosterone ( DHT ), resulting in a reduction in DHT concentrat ... read article

Secondary exposure to Testosterone gel

The FDA ( Food and Drug Administration ) announced that it is requiring manufacturers of two prescription topical testosterone gel products, AndroGel 1% and Testim 1%, to include a boxed warning on th ... read article

FDA has approved Degarelix for patients with advanced prostate cancer

The FDA ( Food and Drug Administration ) has approved the injectable drug Degarelix, the first new drug in several years for prostate cancer. Degarelix is intended to treat patients with advanced ... read article

Prostate cancer: androgen deprivation therapy increases fracture risk

Men with history of fracture and comorbidities are at an increased risk of fracture after long-term use of androgen deprivation therapy, and initiating this therapy should be carefully considered in o ... read article

Focus

New indication for Eylea in EU: treatment of visual impairment due to macular edema secondary to central retinal vein occlusion

Bayer HealthCare has announced that Eylea ( Aflibercept solution for injection ) has been approved by the European Commission ( EC ) for the treatment of visual impairment due to macular edema seconda ... read article

Ibrutinib shows efficacy as treatment for chronic lymphocytic leukemia and mantle cell lymphoma

Two clinical studies published in the New England Journal of Medicine ( NEJM ) suggest that the novel agent Ibrutinib shows real potential as a safe, effective, targeted treatment for adults with chro ... read article

Olmesartan Medoxomil can cause sprue-like enteropathy

FDA ( Food and Drug Administration ) has warned that the blood pressure drug Olmesartan Medoxomil ( marketed as Benicar, Benicar HCT, Azor, Tribenzor, and generics ) can cause intestinal problems know ... read article

Barrett's esophagus: Acetylsalicylic acid may fight cancer by slowing DNA damage

Aspirin ( Acetylsalicylic acid ) is known to lower risk for some cancers, and a new study led by a UC San Francisco researcher, Carlo Maley, points to a possible explanation, with the discovery that A ... read article

Metastatic or unresectable melanoma: FDA approves Tafinlar and Mekinist

The Food and Drug Administration ( FDA ) has approved two new drugs, Tafinlar ( Dabrafenib ) and Mekinist ( Trametinib ), for patients with advanced ( metastatic ) or unresectable melanoma, the most d ... read article

Giant cell tumor of the bone: FDA approves Xgeva

The Food and Drug Administration ( FDA ) has expanded the use of Xgeva ( Denosumab ) to treat adults and some adolescents with giant cell tumor of the bone ( GCTB ), a rare and usually non-cancerous t ... read article

Riociguat has demonstrated significant and sustained improvements in 6MWD and WHO functional class in patients with pulmonary arterial hypertension

Data from the interim analysis of the on-going PATENT-2 trial with Riociguat, the open-label long-term extension of the pivotal Phase III study PATENT-1, were presented at the American Thoracic Societ ... read article

Canagliflozin, a SGLT2 inhibitor, for the treatment of adults with type 2 diabetes

Janssen Pharmaceuticals has announced the FDA ( Food and Drug Administration ) has approved Invokana ( Canagliflozin ) for the treatment of adults with type 2 diabetes. Invokana is the first in a new ... read article